These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 29867345)

  • 1. Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies.
    Xiang C; Zhang S; Dong X; Ma S; Cong S
    Front Mol Neurosci; 2018; 11():153. PubMed ID: 29867345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of SCA3 and implications for other polyglutamine diseases.
    McLoughlin HS; Moore LR; Paulson HL
    Neurobiol Dis; 2020 Feb; 134():104635. PubMed ID: 31669734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
    Bogomazova AN; Eremeev AV; Pozmogova GE; Lagarkova MA
    Mol Biol (Mosk); 2019; 53(6):954-967. PubMed ID: 31876275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyglutamine (PolyQ) diseases: genetics to treatments.
    Fan HC; Ho LI; Chi CS; Chen SJ; Peng GS; Chan TM; Lin SZ; Harn HJ
    Cell Transplant; 2014; 23(4-5):441-58. PubMed ID: 24816443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy and Polyglutamine Disease.
    Ren H; Hao Z; Wang G
    Adv Exp Med Biol; 2020; 1207():149-161. PubMed ID: 32671744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration.
    Tenchov R; Sasso JM; Zhou QA
    ACS Chem Neurosci; 2024 Aug; 15(15):2665-2694. PubMed ID: 38996083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyglutamine disease proteins: Commonalities and differences in interaction profiles and pathological effects.
    Bonsor M; Ammar O; Schnoegl S; Wanker EE; Silva Ramos E
    Proteomics; 2024 Jun; 24(12-13):e2300114. PubMed ID: 38615323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetics and biomarkers of polyglutamine diseases.
    Katsuno M; Banno H; Suzuki K; Takeuchi Y; Kawashima M; Tanaka F; Adachi H; Sobue G
    Curr Mol Med; 2008 May; 8(3):221-34. PubMed ID: 18473821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Expanding Clinical Universe of Polyglutamine Disease.
    Huang S; Zhu S; Li XJ; Li S
    Neuroscientist; 2019 Oct; 25(5):512-520. PubMed ID: 30614396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juvenile Huntington's Disease and Other PolyQ Diseases, Update on Neurodevelopmental Character and Comparative Bioinformatic Review of Transcriptomic and Proteomic Data.
    Świtońska-Kurkowska K; Krist B; Delimata J; Figiel M
    Front Cell Dev Biol; 2021; 9():642773. PubMed ID: 34277598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased aggregation of polyleucine compared with that of polyglutamine in dentatorubral-pallidoluysian atrophy protein.
    Suzuki Y; Jin C; Yazawa I
    Neurosci Lett; 2013 Sep; 552():156-61. PubMed ID: 23933208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular biology of polyglutamine diseases].
    Owecki M; Kozubski W
    Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology.
    Stoyas CA; La Spada AR
    Handb Clin Neurol; 2018; 147():143-170. PubMed ID: 29325609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studying polyglutamine diseases in Drosophila.
    Xu Z; Tito AJ; Rui YN; Zhang S
    Exp Neurol; 2015 Dec; 274(Pt A):25-41. PubMed ID: 26257024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations.
    Wanker EE
    Biol Chem; 2000; 381(9-10):937-42. PubMed ID: 11076024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential therapeutic targets in polyglutamine-mediated diseases.
    Katsuno M; Watanabe H; Yamamoto M; Sobue G
    Expert Rev Neurother; 2014 Oct; 14(10):1215-28. PubMed ID: 25190502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS.
    Hirunagi T; Sahashi K; Tachikawa K; Leu AI; Nguyen M; Mukthavaram R; Karmali PP; Chivukula P; Tohnai G; Iida M; Onodera K; Ohyama M; Okada Y; Okano H; Katsuno M
    Mol Ther Nucleic Acids; 2021 Jun; 24():1-10. PubMed ID: 33738134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms mediating spinal and bulbar muscular atrophy: investigations into polyglutamine-expanded androgen receptor function and dysfunction.
    Beitel LK; Alvarado C; Mokhtar S; Paliouras M; Trifiro M
    Front Neurol; 2013; 4():53. PubMed ID: 23720649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-expression Patterns between
    Keo A; Aziz NA; Dzyubachyk O; van der Grond J; van Roon-Mom WMC; Lelieveldt BPF; Reinders MJT; Mahfouz A
    Front Mol Neurosci; 2017; 10():399. PubMed ID: 29249939
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.